Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

USA News Group News Commentary

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, June 18, 2025 /CNW/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs, and their lack of life-extension successes. That said, with the recent close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers remain optimistic. For investors to note, oncology innovators have provided recent developments to pay attention to, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Galectin Therapeutics, Inc. (NASDAQ: GALT), ProPhase Labs, Inc. (NASDAQ:PRPH), CG Oncology, Inc. (NASDAQ:CGON), and Perspective Therapeutics, Inc. (NYSE-American:CATX).